# EDGAR Filing Document

**Accession Number:** 0001882782
**File Stem:** 0001193125-26-212775
**Filing Date:** 2026-5
**Character Count:** 18570
**Document Hash:** 5fe922a5d14b021aed2160036edccd51
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-212775.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001193125-26-212775

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**EFFECTIVENESS DATE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Odyssey Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001882782
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863384382
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295677
- **FILM NUMBER:** 26955639

**BUSINESS ADDRESS:**
- **STREET 1:** 51 SLEEPER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (212) 841-1000

**MAIL ADDRESS:**
- **STREET 1:** 51 SLEEPER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**As filed with the Securities and Exchange Commission on May 7, 2026** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-1** 

**REGISTRATION STATEMENT** 

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

------

**ODYSSEY THERAPEUTICS, INC.** 

**(Exact Name of Registrant as Specified in Its Charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **2836** | **86-3384382** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(Primary Standard Industrial**<br>**Classification Code Number)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

**51 Sleeper Street** 

**Suite 800**

**Boston, Massachusetts 02210** 

**(617) 865-9628** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

------

**Gary D. Glick, Ph.D.** 

**President and Chief Executive Officer** 

**Odyssey Therapeutics, Inc.** 

**51 Sleeper Street** 

**Suite 800**

**Boston, Massachusetts 02210** 

**(617) 865-9628**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copies to:*** 

---

| | | |
|:---|:---|:---|
| **Brian K. Rosenzweig**<br>**Alicia Zhang**<br>**Joseph Gangitano**<br>**Megan N. Gates**<br>**Covington & Burling LLP**<br>**One International Place, Suite 1020**<br>**Boston, Massachusetts 02110**<br>**(617) 603-8805** | **Jolie M. Siegel**<br>**Executive Vice President, General Counsel and Secretary**<br>**Odyssey Therapeutics, Inc.**<br>**51 Sleeper Street**<br>**Suite 800**<br>**Boston, Massachusetts 02210**<br>**(617) 865-9628** | **Eric Blanchard**<br>**Richard Segal**<br>**Divakar Gupta**<br>**Evan Leitner**<br>**Cooley LLP**<br>**500 Boylston Street**<br>**Boston, Massachusetts 02116**<br>**(617) 937-2300** |

---

------

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after this registration statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-295141

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**This registration statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.**

------

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE**

This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"), for the sole purpose of increasing the aggregate number of shares of common stock offered by Odyssey Therapeutics, Inc. (the "Registrant") by 2,599,000 shares, 339,000 of which are subject to purchase upon exercise of the underwriters' option to purchase additional shares of the Registrant's common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-295141), including all exhibits thereto (the "Prior Registration Statement"), filed by the Registrant with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act and declared effective by the Commission on May 7, 2026, are incorporated by reference into this Registration Statement. The additional shares of common stock that are being registered for issuance and sale pursuant to this Registration Statement are in an amount and at a price that together represents no more than 20% of the maximum aggregate offering price set forth in the filing fee table filed as Exhibit 107 of the Prior Registration Statement.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 5.1 | [<u>Opinion of Covington & Burling LLP.</u>](odtx-ex5_1.htm) |
| 23.1 | [<u>Consent of Deloitte & Touche LLP, independent registered public accounting firm of Odyssey Therapeutics, Inc.</u>](odtx-ex23_1.htm) |
| 23.2 | [<u>Consent of Covington & Burling LLP (included in Exhibit 5.1 to this Registration Statement).</u>](odtx-ex23_1.htm) |
| 24.1 | [<u>Power of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement).</u>](https://www.sec.gov/Archives/edgar/data/1882782/000119312526161514/odtx-20260417.htm#power_of_attorney) |
| 107 | [<u>Filing Fee Table.</u>](odtx-exfiling_fees.htm) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Boston, Massachusetts, on the 7th day of May, 2026.

---

| | |
|:---|:---|
| **Odyssey Therapeutics, Inc.** | **Odyssey Therapeutics, Inc.** |
| By: | /s/ Gary D. Glick |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Gary D. Glick, Ph.D. |
|  | Title: President and Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | &nbsp;&nbsp;**Title** | &nbsp;&nbsp;**Date** |
| /s/ Gary D. Glick | &nbsp;&nbsp;President, Chief Executive Officer and Director (Principal Executive Officer) | May 7, 2026 |
| Gary D. Glick, Ph.D. | &nbsp;&nbsp;President, Chief Executive Officer and Director (Principal Executive Officer) |  |
| /s/ Jason Haas | &nbsp;&nbsp;Chief Financial Officer (Principal Financial and Accounting Officer) | May 7, 2026 |
| Jason Haas | &nbsp;&nbsp;Chief Financial Officer (Principal Financial and Accounting Officer) |  |
| \* | &nbsp;&nbsp;Chairman, Director | May 7, 2026 |
| Jeffrey M. Leiden, M.D., Ph.D. |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Shelley Chu, M.D., Ph.D. |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Paulina Hill, Ph.D. |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Nan Li |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Carolyn Ng, Ph.D. |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Ian F. Smith |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Valerie Odegard, Ph.D. |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Ksenija Pavletic |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Nia Tatsis, Ph.D. |  |  |
| \* | &nbsp;&nbsp;Director | May 7, 2026 |
| Timothy P. Walbert |  |  |

---

---

| | |
|:---|:---|
| \*By: | /s/ Gary D. Glick |
|  | Gary D. Glick, Ph.D. |
|  | Attorney-in-Fact |

---

------

## Exhibit 5.1

---

| | |
|:---|:---|
| ![img202443603_0.jpg](img202443603_0.jpg) | Covington & Burling LLP |
| BEIJING BOSTON BRUSSELS DUBAI FRANKFURT | 30 Hudson Yards |
| JOHANNESBURG LONDON LOS ANGELES NEW YORK | New York, NY 10001-2170 |
| PALO ALTO SAN FRANCISCO SEOUL SHANGHAI WASHINGTON | T +1 212 841 1000 |

---

**Exhibit 5.1**

May 7, 2026

Odyssey Therapeutics, Inc.

51 Sleeper Street, Suite 800

Boston, Massachusetts 02210

Ladies & Gentlemen:

We have acted as counsel to Odyssey Therapeutics, Inc., a Delaware corporation (the "*Company*"), and are rendering this opinion in connection with the registration by the Company under the Securities Act of 1933 (the "*Securities Act*") of the offer and sale of up to 2,599,000 shares (the "*Shares*") of the Company's common stock, par value $0.0001 per share (the "*Common Stock*"), pursuant to the registration statement on Form S-1 filed with the United States Securities and Exchange Commission on May 7, 2026, pursuant to Rule 462(b) under the Securities Act (the "*Registration Statement*"). The Registration Statement incorporates by reference the registration statement on Form S-1 (File No. 333-295141) (as amended, the "*Prior Registration Statement*").

We have reviewed the Registration Statement, the Prior Registration Statement, and such corporate records, certificates and other documents, and such questions of law, as we have deemed necessary or appropriate for the purposes of this opinion. We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals. We have also assumed that the Shares will be duly registered on the books of the transfer agent and registrar of the Common Stock and that the Company will comply with applicable notice requirements regarding uncertificated shares provided under the Delaware General Corporation Law (the "*DGCL*"). We have assumed further that, except as to legal conclusions expressly set forth in this opinion, the information and representations and warranties contained in the agreements, instruments, records, certificates and other documents we reviewed were true, accurate and complete as of their stated date and are true, accurate and complete as of the date of this letter.

We have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources believed by us to be responsible.

Based upon the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Registration Statement has become effective under the Securities Act, the Shares, when duly issued and sold as contemplated in the Registration Statement, will be validly issued, fully paid and non-assessable.

We are members of the bar of the State of New York. We do not express any opinion herein on any laws other than the DGCL.

------

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. We also hereby consent to the reference to our firm under the heading "Legal Matters" in the prospectus constituting part of the Prior Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

---

| |
|:---|
| Very truly yours, |
| /s/ Covington & Burling LLP |

---

------

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in this registration statement on Form S-1 of our report dated March 16, 2026 (May 4, 2026, as to the effects of the reverse stock split discussed in Note 19), relating to the financial statements of Odyssey Therapeutics, Inc., appearing in registration statement No. 333-295141 on Form S-1 of Odyssey Therapeutics, Inc.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

May 7, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Odyssey Therapeutics, Inc.**  |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation or Carry Forward Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Common Stock, par value $0.0001 per share | 457(a) | 2599000 | $18.00 | $46782000.00 | 0.0001381 | $6460.59 |
| Fees Previously Paid |  |  |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $46782000.00  |  | $6460.59  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $6460.59  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> 1 The Registrant previously registered securities with a proposed maximum aggregate offering price not to exceed $274,068,000.00 on a Registration Statement on Form S-1 (File No. 333-295141), as amended, which was declared effective by the Securities and Exchange Commission on May 7, 2026 (the "Prior Registration Statement"). In accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended, an additional amount of securities having a proposed maximum aggregate offering price of $46,782,000.00 is hereby registered, which includes the shares of common stock that the underwriters have the option to purchase.

---

| |
|:---|
| |
| **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims |
| Fee Offset Sources |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---